Cargando…
On the path to 2025: understanding the Alzheimer’s disease continuum
Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease and the spectrum of AD spans from clinically asymptomatic to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549378/ https://www.ncbi.nlm.nih.gov/pubmed/28793924 http://dx.doi.org/10.1186/s13195-017-0283-5 |
_version_ | 1783255966867783680 |
---|---|
author | Aisen, Paul S. Cummings, Jeffrey Jack, Clifford R. Morris, John C. Sperling, Reisa Frölich, Lutz Jones, Roy W. Dowsett, Sherie A. Matthews, Brandy R. Raskin, Joel Scheltens, Philip Dubois, Bruno |
author_facet | Aisen, Paul S. Cummings, Jeffrey Jack, Clifford R. Morris, John C. Sperling, Reisa Frölich, Lutz Jones, Roy W. Dowsett, Sherie A. Matthews, Brandy R. Raskin, Joel Scheltens, Philip Dubois, Bruno |
author_sort | Aisen, Paul S. |
collection | PubMed |
description | Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease and the spectrum of AD spans from clinically asymptomatic to severely impaired. Defining AD purely by its clinical presentation is thus artificial and efforts have been made to recognize the disease based on both clinical and biomarker findings. Advances with biomarkers have also prompted a shift in how the disease is considered as a clinico-pathophysiological entity, with an increasing appreciation that AD should not only be viewed with discrete and defined clinical stages, but as a multifaceted process moving along a seamless continuum. Acknowledging this concept is critical to understanding the development process for disease-modifying therapies, and for initiating effective diagnostic and disease management options. In this article, we discuss the concept of a disease continuum from pathophysiological, biomarker, and clinical perspectives, and highlight the importance of considering AD as a continuum rather than discrete stages. While the pathophysiology of AD has still not been elucidated completely, there is ample evidence to support researchers and clinicians embracing the view of a disease continuum in their study, diagnosis, and management of the disease. |
format | Online Article Text |
id | pubmed-5549378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55493782017-08-11 On the path to 2025: understanding the Alzheimer’s disease continuum Aisen, Paul S. Cummings, Jeffrey Jack, Clifford R. Morris, John C. Sperling, Reisa Frölich, Lutz Jones, Roy W. Dowsett, Sherie A. Matthews, Brandy R. Raskin, Joel Scheltens, Philip Dubois, Bruno Alzheimers Res Ther Review Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer’s disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease and the spectrum of AD spans from clinically asymptomatic to severely impaired. Defining AD purely by its clinical presentation is thus artificial and efforts have been made to recognize the disease based on both clinical and biomarker findings. Advances with biomarkers have also prompted a shift in how the disease is considered as a clinico-pathophysiological entity, with an increasing appreciation that AD should not only be viewed with discrete and defined clinical stages, but as a multifaceted process moving along a seamless continuum. Acknowledging this concept is critical to understanding the development process for disease-modifying therapies, and for initiating effective diagnostic and disease management options. In this article, we discuss the concept of a disease continuum from pathophysiological, biomarker, and clinical perspectives, and highlight the importance of considering AD as a continuum rather than discrete stages. While the pathophysiology of AD has still not been elucidated completely, there is ample evidence to support researchers and clinicians embracing the view of a disease continuum in their study, diagnosis, and management of the disease. BioMed Central 2017-08-09 /pmc/articles/PMC5549378/ /pubmed/28793924 http://dx.doi.org/10.1186/s13195-017-0283-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Aisen, Paul S. Cummings, Jeffrey Jack, Clifford R. Morris, John C. Sperling, Reisa Frölich, Lutz Jones, Roy W. Dowsett, Sherie A. Matthews, Brandy R. Raskin, Joel Scheltens, Philip Dubois, Bruno On the path to 2025: understanding the Alzheimer’s disease continuum |
title | On the path to 2025: understanding the Alzheimer’s disease continuum |
title_full | On the path to 2025: understanding the Alzheimer’s disease continuum |
title_fullStr | On the path to 2025: understanding the Alzheimer’s disease continuum |
title_full_unstemmed | On the path to 2025: understanding the Alzheimer’s disease continuum |
title_short | On the path to 2025: understanding the Alzheimer’s disease continuum |
title_sort | on the path to 2025: understanding the alzheimer’s disease continuum |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549378/ https://www.ncbi.nlm.nih.gov/pubmed/28793924 http://dx.doi.org/10.1186/s13195-017-0283-5 |
work_keys_str_mv | AT aisenpauls onthepathto2025understandingthealzheimersdiseasecontinuum AT cummingsjeffrey onthepathto2025understandingthealzheimersdiseasecontinuum AT jackcliffordr onthepathto2025understandingthealzheimersdiseasecontinuum AT morrisjohnc onthepathto2025understandingthealzheimersdiseasecontinuum AT sperlingreisa onthepathto2025understandingthealzheimersdiseasecontinuum AT frolichlutz onthepathto2025understandingthealzheimersdiseasecontinuum AT jonesroyw onthepathto2025understandingthealzheimersdiseasecontinuum AT dowsettsheriea onthepathto2025understandingthealzheimersdiseasecontinuum AT matthewsbrandyr onthepathto2025understandingthealzheimersdiseasecontinuum AT raskinjoel onthepathto2025understandingthealzheimersdiseasecontinuum AT scheltensphilip onthepathto2025understandingthealzheimersdiseasecontinuum AT duboisbruno onthepathto2025understandingthealzheimersdiseasecontinuum |